Illumina has introduced a suite of advanced multiomic technologies aimed at revolutionizing biological research and precision medicine. These innovations span genomics, spatial transcriptomics, single-cell analysis, CRISPR, epigenetics, and data analytics. They are designed to provide researchers with unprecedented insights into the mechanisms of disease.

Built on Illumina’s highly accurate sequencing platforms, these advanced solutions for biological research aim to surpass current industry standards in scale, accuracy, and reliability. Key highlights include the development of constellation-mapped reads for enhanced rare disease detection, a single-cell CRISPR research tool for large-scale Perturb-seq experiments, and a five-base methylation analysis solution for simultaneous genetic and epigenetic profiling. Additionally, Illumina’s new spatial transcriptomics technology promises to deliver cellular-level resolution across millions of cells. Complementing these advancements is the Illumina Connected Multiomics platform, a user-friendly software designed to streamline the analysis of complex multimodal datasets.

Image Credit: Illumina